Wall Street analysts expect Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) to post earnings per share of ($0.12) for the current quarter, according to Zacks. Three analysts have issued estimates for Rigel Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.11) and the lowest estimate coming in at ($0.13). Rigel Pharmaceuticals posted earnings of ($0.19) per share in the same quarter last year, which suggests a positive year over year growth rate of 36.8%. The firm is expected to announce its next earnings report on Tuesday, May 2nd.

According to Zacks, analysts expect that Rigel Pharmaceuticals will report full-year earnings of ($0.50) per share for the current financial year, with EPS estimates ranging from ($0.59) to ($0.36). For the next financial year, analysts expect that the company will post earnings of ($0.38) per share, with EPS estimates ranging from ($0.55) to ($0.17). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Rigel Pharmaceuticals.

Rigel Pharmaceuticals (NASDAQ:RIGL) last issued its earnings results on Tuesday, March 7th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.01. Rigel Pharmaceuticals had a negative net margin of 255.84% and a negative return on equity of 86.54%. The company had revenue of $3 million for the quarter, compared to analyst estimates of $4.25 million. During the same period in the prior year, the business posted ($0.14) earnings per share. The firm’s revenue for the quarter was down 64.9% compared to the same quarter last year.

This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/04/20/brokerages-anticipate-rigel-pharmaceuticals-inc-rigl-will-post-earnings-of-0-12-per-share.html

Several equities analysts have recently issued reports on the stock. Jefferies Group LLC reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Rigel Pharmaceuticals in a research note on Wednesday, March 8th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $4.00 price objective on shares of Rigel Pharmaceuticals in a research note on Monday, January 30th. Zacks Investment Research cut shares of Rigel Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, December 31st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective (down previously from $6.00) on shares of Rigel Pharmaceuticals in a research note on Thursday, March 9th. Seven analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and a consensus price target of $5.50.

TRADEMARK VIOLATION WARNING: “Brokerages Anticipate Rigel Pharmaceuticals, Inc. (RIGL) Will Post Earnings of -$0.12 Per Share” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/04/20/brokerages-anticipate-rigel-pharmaceuticals-inc-rigl-will-post-earnings-of-0-12-per-share.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. FMR LLC increased its position in Rigel Pharmaceuticals by 4.6% in the fourth quarter. FMR LLC now owns 14,833,279 shares of the biotechnology company’s stock valued at $35,303,000 after buying an additional 652,133 shares during the period. JPMorgan Chase & Co. increased its position in Rigel Pharmaceuticals by 36.1% in the third quarter. JPMorgan Chase & Co. now owns 2,162,247 shares of the biotechnology company’s stock valued at $7,936,000 after buying an additional 573,522 shares during the period. Rock Springs Capital Management LP increased its position in Rigel Pharmaceuticals by 3.4% in the third quarter. Rock Springs Capital Management LP now owns 1,810,000 shares of the biotechnology company’s stock valued at $6,643,000 after buying an additional 60,000 shares during the period. State Street Corp increased its position in Rigel Pharmaceuticals by 7.1% in the fourth quarter. State Street Corp now owns 1,712,369 shares of the biotechnology company’s stock valued at $4,070,000 after buying an additional 112,796 shares during the period. Finally, State of New Jersey Common Pension Fund D increased its position in Rigel Pharmaceuticals by 54.5% in the third quarter. State of New Jersey Common Pension Fund D now owns 850,000 shares of the biotechnology company’s stock valued at $3,120,000 after buying an additional 300,000 shares during the period. 72.23% of the stock is currently owned by institutional investors and hedge funds.

Rigel Pharmaceuticals (NASDAQ:RIGL) opened at 3.05 on Thursday. The firm’s market capitalization is $372.97 million. The firm’s 50-day moving average is $3.01 and its 200 day moving average is $2.75. Rigel Pharmaceuticals has a 12 month low of $1.94 and a 12 month high of $4.38.

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology. The Company’s clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase III clinical trials for immune thrombocytopenic purpura (ITP); a Phase II clinical trial for autoimmune hemolytic anemia (AIHA), and a Phase II clinical trial for IgA nephropathy (IgAN).

5 Day Chart for NASDAQ:RIGL

Get a free copy of the Zacks research report on Rigel Pharmaceuticals (RIGL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Rigel Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.